Hematologic Oncology

Genzyme Corporation announced that the FDA has approved its new manufacturing plant in Framingham, Massachusetts.

Dr. James Berenson, from the Institute for Myeloma and Bone Cancer Research, Discusses Early Phase Proteasome Inhibitors

The FDA has deemed subcutaneous injection as a safe and valid method of delivering the drug bortezomib in patients with multiple myeloma.

While she attributes her survival to her oncologists and the care they provided, Maryclaire is quick to stress the difference between surviving and living, noting that it was her friends and family who gave her what she needed to truly recover.

A mixed treatment comparison demonstrated that FCR significantly prolonged PFS compared with all other treatments and significantly increased ORR compared with all other treatments.

Dr. Susan O'Brien, from the MD Anderson Cancer Center, Discusses the Standard of Care for CLL

Dr. Maria Cappellini, Maggiore Hospital, Milan, Italy, on Splenectomy in Gaucher Disease Patients.

The FDA and Seattle Genetics announced that new warning labels would be issued for brentuximab vedotin.

Several advancements in research and drug approvals have changed the landscape of care for optimal treatment in patients with lymphoma, leukemia, and myeloma.

FISH testing for genetic abnormalities is the key to appropriate treatment selection for patients with CLL.

Several molecular markers for AML are now used at top-tier cancer centers for prediction, treatment selection, and monitoring response.

Genetic markers are becoming a more integral part of diagnosing cancer and determining which patients will encounter more aggressive forms of their disease.

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses the Winter Hematology Meeting

Dr. Elena Lukina Discusses Timely Gaucher Disease Diagnosis

Dr. Laurie Sehn, from the British Columbia Cancer Agency, Discusses the GAUSS Obinutuzumab Trial

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses Brentuximab Vedotin

Dr. Daniel Couriel, from the Unversity of Michigan Comprehensive Cancer Center, Discusses Treating GVHD With Photopheresis

Bone disease occurs in about 84% of patients with multiple myeloma and is responsible for a great deal of morbidity, including pain, hypercalcemia, compromised quality of life, and pathological fracture.

Dr. Tatyana Feldman, from the John Theurer Cancer Center, Discusses Using Doxil for CTCL

Because of bendamustine's potential to cause pain and erythema to the extent that hospitalization has been required for some patients, it would be prudent to administer bendamustine using vesicant precautions.

Trainees have sat in this hot seat at the front of the room for decades. It's not really warm, of course. This is where the fellow sits who is asked to review the findings, come up with a differential diagnosis, and devise a plan for the case in question.

While debt from medical school loans is inevitable for most oncology and hematology fellows, there are strategies they can consider to lessen that burden.

Dr. Anthony Mato From the John Theurer Cancer Center Discusses the Benefits of the JTCC Retrospective Trial

The phase III VISTA trial upholds a persistent and statistically significant survival benefit for bortezomib in previously untreated multiple myeloma patients.

Treatment with GA101 (obinutuzumab) in patients with relapsed non-Hodgkin lymphoma (NHL) resulted in higher response rates compared with rituximab.